Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial. (April 2021)

Record Type:: Journal Article
Title:: Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial. (April 2021)
Main Title:: Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
Authors:: Martin, M.
Holmes, F.A.
Moy, B.
Mansi, J.
Gnant, M.
Buyse, M.
Barrios, C.
Bryce, R.
Wong, A.
Chan, A.
Abstract:
Is Part Of:: Breast. Volume 56(2021)Supplement 1
Journal:: Breast
Issue:: Volume 56(2021)Supplement 1
Issue Display:: Volume 56, Issue 2021 (2021)
Year:: 2021
Volume:: 56
Issue:: 2021
Issue Sort Value:: 2021-0056-2021-0000
Page Start:: S19
Page End:
Publication Date:: 2021-04
Subjects:: Breast -- Diseases -- Periodicals
Breast -- Tumors -- Periodicals
Breast -- Periodicals
Electronic journals
Periodicals
616
Journal URLs:: http://www.sciencedirect.com/science/journal/09609776 ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0960-9776;screen=info;ECOIP ↗
http://www.harcourt-international.com/journals/brst/ ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09609776 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09609776 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0960-9776(21)00093-X ↗
Languages:: English
ISSNs:: 0960-9776
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 2277.492700
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 16180.xml